Background: The objectives of this study aimed to detect a CYP2B6 polymorphism in de novo cases of acutemyeloid leukemia patients and identify any role in disease progression and outcome. Materials and
Methods:DNA was isolated from peripheral blood of 82 newly diagnosed acute myeloid leukemia cases and the CYP2B6G15631T gene polymorphism was assayed by PCR restriction fragment length polymorphism (PCR-RFLP).
Results: The frequency of the GG genotype (wild type) was 48 (58.5%) and that of the mutant type T allele was 34(41.9%). GT genotype heterozygous variants were found in 28 (34%), and TT genotype homozygous variants in6 (7.3%) cases. We found no significant association between the CYP2B6 G15631T polymorphism and completeresponse (CR) (p-value=0.768), FAB classification (p-value=0.51), cytogenetic analysis (p-value=0.673), and overallsurvival (p-value=0.325). Also, there were no significant links with early toxic death (p-value=0.92) or progressionfreesurvival (PFS) (p-value=0.245).
Conclusions: Our results suggest that the CYP2B6 polymorphism has norole in disease progression, therapeutic outcome, patient free survival, early toxic death and overall survival inacute myeloid leukemia patients.